Is Sakar Healthcare a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Sakar Healthcare Ltd is a average quality company .

Is Sakar Healthcare undervalued or overvalued?

The key valuation ratios of Sakar Healthcare Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Sakar Healthcare share price return in the past 10 years?

Data is not available for this company

Is Sakar Healthcare a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Sakar Healthcare Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

Sakar Healthcare Ltd - Stock Valuation and Financial Performance

Name: Sakar Healthcare
Brand: Sakar Healthcare

BSE: 0 | NSE: SAKAR | Pharmaceuticals & Drugs | Small Cap

Place order

BSE Share Price
Not Listed

10 Year X-Ray of Sakar Healthcare:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	13.9%	15.3%	16.1%	14.2%	15.5%	16%	13.2%	12.1%	9%	7.4%	-
Value Creation Index ⓘ	0.0	0.1	0.2	0.0	0.1	0.1	-0.1	-0.1	-0.4	-0.5	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	35	41.2	44.2	53.1	68.3	83	94.7	128	133	153	164
Sales YoY Gr.	-	17.7%	7.1%	20.2%	28.6%	21.6%	14.2%	35.4%	4%	15%	-
Adj EPS ⓘ	2.3	2.9	3	3	4.4	6	6.6	8.4	5.4	4.7	5.7
YoY Gr.	-	26.5%	4.5%	-0.3%	46.2%	36.1%	9.1%	27.7%	-35.4%	-13.1%	-
BVPS (₹) ⓘ	18.5	21.5	32.4	38.3	48	54.4	63	74.5	91.1	118.4	121.8
Adj Net Profit ⓘ	1.8	2.3	3.3	3.7	6.6	9	10.3	14.4	10.3	10.3	12
Cash Flow from Ops. ⓘ	4.2	9.2	9.2	5.3	16.1	18.8	14.6	35.8	33.3	24.5	-
Debt/CF from Ops. ⓘ	5.9	2.1	2.3	2.8	0.7	0.9	2.9	2.6	3.6	3.2	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	17.8%	17.6%	17.4%	15%
Adj EPS ⓘ	8.3%	1.3%	-10.5%	-13.1%
BVPSⓘ	22.9%	19.8%	23.4%	30%
Share Price	-	42.8%	24.8%	-27.9%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	12.8	14.6	12.7	8.5	10.8	11.8	11.4	12.7	6.9	4.7	4.8
Op. Profit Mgn % ⓘ	22.5	20.2	23	23.7	24.7	23.6	23.9	22.9	24.9	25	25.7
Net Profit Mgn % ⓘ	5.2	5.7	7.6	7	9.7	10.9	10.9	11.2	7.8	6.7	7.6
Debt to Equity ⓘ	1.7	1.1	0.6	0.3	0.2	0.2	0.4	0.7	0.7	0.3	0.2
Working Cap Days ⓘ	142	118	144	167	140	134	184	163	157	159	80
Cash Conv. Cycle ⓘ	65	54	54	61	56	53	32	-7	-2	28	11

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 17.41%

Debt to equity has declined versus last 3 years average to 0.31

Sales growth is good in last 4 quarters at 12.06%

Return on Equity has declined versus last 3 years average to 4.70%

Net Profit has been subdued in last 3 years -10.48%

Latest Financials - Sakar Healthcare Ltd.

	Standalone	Consolidated
TTM EPS (₹)	5.7	5.7
TTM Sales (₹ Cr.)	164	164
BVPS (₹.) ⓘ	121.8	121.7
Reserves (₹ Cr.) ⓘ	243	243
P/BV ⓘ	2.41	2.41
PE ⓘ	51.54	51.54

From the Market
52 Week Low / High (₹)	0.00 / 0.00
All Time Low / High (₹)	- / -
Market Cap (₹ Cr.)	639
Equity (₹ Cr.)	21.8
Face Value (₹)	10
Industry PE ⓘ	43

Management X-Ray of Sakar Healthcare:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Sakar Healthcare

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Sakar Healthcare

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	35	41	44	53	68	83	95	128	133	153
Operating Expenses ⓘ	27	33	34	41	51	63	72	99	100	115
Manufacturing Costs	4	4	3	3	4	5	3	4	4	6
Material Costs	17	22	22	28	35	43	51	74	74	84
Employee Cost	4	4	6	7	8	12	13	14	16	19
Other Costs ⓘ	2	2	3	3	3	4	5	6	7	7
Operating Profit ⓘ	8	8	10	13	17	20	23	29	33	38
Operating Profit Margin (%)	22.5%	20.2%	23.0%	23.7%	24.7%	23.6%	23.9%	22.9%	24.9%	25.0%
Other Income ⓘ	0	0	1	1	1	2	1	2	5	3
Interest ⓘ	3	3	3	3	2	2	2	3	6	8
Depreciation ⓘ	2	3	3	4	6	7	8	10	15	18
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	2	3	5	6	9	12	13	19	17	16
Tax ⓘ	1	1	1	2	3	3	3	4	4	4
Profit After Tax	2	2	3	4	7	10	11	15	13	12
PAT Margin (%)	5.2%	5.6%	7.6%	7.2%	9.8%	11.6%	11.3%	11.9%	9.6%	7.6%
Adjusted EPS (₹)	2.3	2.9	3.1	3.1	4.5	6.4	6.9	8.9	6.7	5.4
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	15	17	36	47	72	81	98	128	173	258
Share Capital ⓘ	8	8	11	12	15	15	16	17	19	22
Reserves ⓘ	7	9	25	35	57	66	83	110	154	236
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	25	19	21	11	8	15	40	90	111	69
Long Term Debt	19	15	16	10	5	12	38	85	98	55
Short Term Debt	6	4	5	1	3	2	2	5	13	14
Trade Payables	1	4	3	4	4	5	20	31	26	27
Others Liabilities ⓘ	10	11	11	19	14	14	19	20	26	35
Total Liabilities ⓘ	50	51	71	81	97	115	178	268	336	389
Fixed Assets
Gross Block	49	53	68	76	70	79	90	235	305	371
Accumulated Depreciation	13	15	19	23	6	13	21	31	38	56
Net Fixed Assetsⓘ	36	37	49	53	64	66	69	205	267	314
CWIP ⓘ	0	0	0	0	9	13	49	1	6	0
Investmentsⓘ	0	0	0	0	0	0	0	7	3	0
Inventories	7	6	7	4	7	11	16	14	15	28
Trade Receivables	2	3	5	11	10	8	12	14	22	21
Cash Equivalents	1	0	0	0	0	0	0	0	0	0
Others Assetsⓘ	4	4	9	13	8	17	32	26	22	25
Total Assets ⓘ	50	51	71	81	97	115	178	268	336	389

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	4	9	9	5	16	19	15	36	33	24
PBT ⓘ	2	3	3	6	9	12	13	19	17	16
Adjustment ⓘ	5	5	5	6	8	9	9	12	20	25
Changes in Working Capital ⓘ	-3	1	1	-6	0	0	-7	4	1	101
Tax Paid ⓘ	-1	-1	-1	-1	-1	-3	-1	0	-4	-117
Cash Flow From Investing Activity ⓘ	-1	-4	-4	-8	-25	-22	-47	-90	-74	-52
Capex	-1	-4	-4	-9	-25	-13	-36	-98	-82	-60
Net Investments	0	0	0	0	0	0	0	-7	4	3
Others ⓘ	0	0	0	1	0	-9	-11	14	4	5
Cash Flow From Financing Activityⓘ	-3	-6	-6	-13	9	3	32	55	41	27
Net Proceeds from Shares ⓘ	0	0	0	-4	13	0	8	10	33	73
Net Proceeds from Borrowing ⓘ	1	-3	-3	-6	0	0	0	0	0	0
Interest Paid ⓘ	-3	-3	-3	-3	-2	-2	-2	-3	-5	-7
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-1	0	0	0	-3	5	26	47	13	-39
Net Cash Flow ⓘ	1	-1	-1	-16	0	0	0	0	0	0

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	13.2	14.56	12.83	9.27	11.29	12.57	11.89	13.49	8.48	5.42
ROCE (%)	13.89	15.29	16.11	14.17	15.45	16.02	13.16	12.13	8.95	7.41
Asset Turnover Ratio	0.68	0.81	0.73	0.7	0.76	0.78	0.65	0.58	0.44	0.42
PAT to CFO Conversion(x)	2	4.5	3	1.25	2.29	1.9	1.36	2.4	2.54	2
Working Capital Days
Receivable Days	22	22	34	56	54	39	40	38	50	51
Inventory Days	71	58	55	37	29	39	51	43	40	51
Payable Days	47	41	58	49	43	40	90	123	140	117

Sakar Healthcare Ltd Stock News

Sakar Healthcare Ltd FAQs

What is the share price of Sakar Healthcare?

Company share prices are keep on changing according to the market conditions. The closing price of Sakar Healthcare on 01-Jan-1970 05:30 is ₹0.00.

What is the market cap of Sakar Healthcare?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Sakar Healthcare stood at ₹639.2.

What is the P/E ratio of Sakar Healthcare?

The latest P/E ratio of Sakar Healthcare as of 01-Jan-1970 05:30 is 51.54.

What is the P/B ratio of Sakar Healthcare?

The latest P/B ratio of Sakar Healthcare as of 01-Jan-1970 05:30 is 2.41.

What is the 52-week high and low of Sakar Healthcare?

The 52-week high of Sakar Healthcare is ₹0.00 and the 52-week low is ₹0.00.

What is the TTM revenue of Sakar Healthcare?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sakar Healthcare is ₹164.2 ( Cr.) .

About Sakar Healthcare Ltd

Having a vision to make lives healthy, happy and more meaningful by providing healthcare solutions, Sakar Healthcare Limited, was incorporated on March 26, 2004. Subsequently, the company was converted into a public limited company and a fresh Certificate of Incorporation consequent upon change of name on Conversion to Public Limited Company dated March 27, 2015 was issued by the Registrar of Companies, Gujarat, Ahmedabad and the name of the company has got changed to 'Sakar Healthcare Limited'.

The company is managed by a team of professionals headed by its Managing Director having experience in manufacturing and export of pharmaceutical and health care products to various countries. Its preliminary business area and key focus was in contract manufacturing in the past years. As a contract manufacturer, the company undertakes manufacturing on behalf of some of the leading pharmaceutical companies in India, in accordance with the terms of the relevant agreements entered into with these companies. The company has registered its products in various countries which are marketed through supply, distribution and other arrangements with various dealers / distributors.

The company’s manufacturing facilities are located at Changodar, Ahmedabad, Gujarat. Its facilities have been approved by various international regulatory authorities such as BVQI, WHO, GM:P, CGMP and National Drug Authority of various countries including Nigeria, Ethopia, Ghana, Bolivia, Yemen and Philippines, Uganda, Ivory Coast, etc.

Business area of the company

The company is an Indian pharmaceutical company engaged in the manufacturing and marketing of its own pharmaceutical formulations for domestic and international markets. Its Product domestic sales are generally exported by third party. It also undertakes contract manufacturing of formulations for pharmaceutical companies based in India. It manufactures and markets pharmaceutical formulations relating to analgesics, antielminthics, anti coagulants, anti malarial, anti spasmodics, antianemics, antibiotics, anti-emetics, anti-histamines, bronchodilators, corticosteroids, cough and cold preparations, multivitamins, etc.